Phase 3Completed

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)

Sponsor
Pfizer (Industry)
Enrollment
270 enrolled
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib
Ages
adults, older adults
Registry
NCT03502616, EUCTR2018-000226-58

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Primary outcomes

  • Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered